This
Accredited Continuing Education Product comprises content captured live from
the American Diabetes Association 67th Scientific Sessions. This program will
allow Diabetes Healthcare Professionals to learn about:
- The gap in current treatments of type 2 diabetes
- Present and future therapies to correct incretin abnormalities
- Research studies involving agents that are members of these
innovative drug classes
- The potential role of these innovative agents in the management
of patients with type 2 diabetes.
Each
presentation includes synchronized slides and audio as well as a written
transcription. Each activity below is individually accredited
by the American Diabetes Association for Physicians,
Physician Assistants, Nurses, Nurse Practitioners, Pharmacists, Dieticians,
Podiatric Physicians, and Certified Diabetes Educators.
AMP Kinase - A Multi-Organ Fuel Sensor
Clinical Relevance of the Beta-Cell ATP-dependent Potassium Channel
Endoplasmic Reticulum Stress in the Beta-Cell
Glucagon Secretion - Bench to Bedside
Hypoglycemic Counterregulation - Modulation, Mechanisms & Clinical Consequences
Incretin Based Therapies- Today and Tomorrow
More Target Practice or the Real Deal? Novel Modulators of Insulin Action
National Diabetes Education Program - Science in the Community - Translating DCCT, UKPDS, EDIC & DPP for Health Care Professionals and People With or At Risk for Diabetes
Pros and Cons of GLP Agonists versus DPP IV Inhibitors
|